GET DAILY SIGNALSGlobal X Genomics & Biotechnology ETF (GNOM): Positioning in a High-Growth Genomics Theme
Key Takeaways
- GNOM is a passively managed exchange-traded fund that tracks the Solactive Genomics Index, focusing on companies advancing genomic science, gene editing, sequencing, and genetic medicine.
- The fund holds roughly 50 securities, concentrated in healthcare and biotechnology, with top positions including Moderna, Twist Bioscience, 10x Genomics, and Illumina.
- Over the trailing 30 days, GNOM has traded roughly flat to slightly lower, while the trailing three-month trend has been notably stronger.
- The portfolio carries a net expense ratio of 0.50% and approximately $102 million in assets under management.
- Principal themes are structural growth in genomics and precision medicine, offset by elevated volatility, unprofitable-biotech risk, and sensitivity to interest rates and risk sentiment.
- Investors can review additional analysis, including Price Targets and Forecast pages, for deeper insight into GNOM.
- Explore Trending AI Robots to discover automated trading strategies and market signals.
Global X Genomics & Biotechnology ETF (GNOM) at a Glance
The Global X Genomics & Biotechnology ETF seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index. The strategy invests in exchange-listed companies positioned to benefit from advances in genomic science and biotechnology, including gene editing, genomic sequencing, genetic medicine and therapy, computational genomics, and related applications.
GNOM is a non-diversified, passively managed index-tracking fund launched in April 2019. It holds approximately 50 securities with a heavy concentration in the healthcare sector, where biotechnology is the dominant industry. The top holdings include Moderna (MRNA), Twist Bioscience (TWST), 10x Genomics (TXG), Illumina (ILMN), and Guardant Health (GH), with additional weight in Natera (NTRA), Vertex Pharmaceuticals (VRTX), and BioMarin Pharmaceutical (BMRN). The top 10 holdings typically account for a substantial share of net assets, and the portfolio is overwhelmingly weighted toward U.S.-listed companies. The net expense ratio is 0.50%.
Industry and Thematic Landscape
GNOM operates at the intersection of healthcare innovation and high-growth, high-volatility biotech. Structural drivers, including falling sequencing costs, the expansion of gene-editing platforms such as CRISPR-based therapies, and the growing adoption of liquid-biopsy diagnostics, continue to underpin long-term demand. At the same time, the segment is sensitive to broader risk appetite, because many constituents are early-stage companies with limited current earnings.
The macroeconomic backdrop matters disproportionately for this fund. Biotech valuations are highly sensitive to interest-rate expectations, since future cash flows are discounted more heavily when rates rise. Inflation and monetary policy, clinical-trial outcomes, regulatory decisions at agencies such as the U.S. Food and Drug Administration, and capital-market conditions for fundraising all influence the sector. Competition from larger pharmaceutical acquirers and the pace of mergers and acquisitions also shape sentiment across the genomics complex.
Performance and Positioning Snapshot
Over the trailing 30 days, GNOM has been broadly range-bound, edging roughly 1% lower as choppy trading in October offset a late-September advance. This near-term consolidation followed a much stronger stretch: over the trailing three months, the fund advanced on the order of 23%, reflecting a mid-summer breakout that lifted the portfolio from the mid-$50s toward the high-$60s per share.
That quarterly move was consistent with a broad biotech re-rating driven by renewed investor interest in weight-loss and precision-medicine pipelines, improved funding conditions, and strength in several large holdings. Moderna, the fund's largest position, has been a standout contributor over the trailing year, while diagnostic and sequencing names such as Natera, Guardant Health, and 10x Genomics have also rallied. These gains have been accompanied by elevated realized volatility, consistent with GNOM's historically high annualized volatility, which has frequently exceeded 30%.
2026 Outlook and Key Factors to Monitor
Several structural factors are likely to shape GNOM through 2026. Interest-rate policy and inflation expectations will remain central, given the portfolio's concentration in long-duration, often unprofitable biotech companies. A more accommodative monetary backdrop has historically been constructive for the sector, while persistent rate pressure tends to compress valuations.
Clinical and regulatory catalysts will also matter. Pipeline readouts across the fund's gene-editing, sequencing, and diagnostic holdings, along with FDA decisions, can produce outsized single-stock moves that ripple through the index. The earnings trajectory of major positions such as Moderna, Vertex, and Illumina warrants close attention, as does the pace of M&A and institutional capital flows into thematic healthcare strategies.
Finally, competition and product cycles in sequencing and diagnostics, the commercialization of genetic medicines, and reimbursement dynamics all represent both risks and opportunities. Investors should monitor these themes alongside the fund's elevated volatility and its concentration in a relatively small number of high-beta names. From what I see, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Using AI Tools for Portfolio Insights
In my analysis of thematic ETFs like GNOM, I find Tickeron’s AI Screener helpful for quickly scanning technical indicators, fundamentals, and AI-generated signals across the genomics space. It allows me to surface comparable names and monitor shifting conditions without manually reviewing hundreds of securities each time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
GNOM in -4.57% downward trend, declining for three consecutive days on October 23, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where GNOM declined for three days, in 281 of 309 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GNOM moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
GNOM broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on GNOM as a result. In 81 of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for GNOM just turned positive on October 28, 2026. Looking at past instances where GNOM's MACD turned positive, the stock continued to rise in 45 of 54 cases over the following month. The odds of a continued upward trend are 83%.
GNOM moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNOM advanced for three days, in 226 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 178 of 194 cases where GNOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement